HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome

Autor: Faruk Skenderi, Mohamad Alhoda Mohamad Alahmad, Emin Tahirovic, Yaman M. Alahmad, Zoran Gatalica, Semir Vranic
Rok vydání: 2022
Předmět:
Zdroj: Breast Cancer Research and Treatment. 193:523-533
ISSN: 1573-7217
0167-6806
DOI: 10.1007/s10549-022-06578-4
Popis: Purpose Apocrine carcinoma of the breast (APO) expresses HER2 in 30–50% of cases. This study explored the clinicopathological features and outcome of HER2+/APO and matched HER2+/NST cohort. Methods We used the SEER database to explore the cohorts. Univariate and multivariate analyses were used to assess the survival. Based on ER and PR [steroid receptors/SR/] and HER2 status, we divided the cohorts to match the intrinsic molecular subtypes for comparisons. Results We retrieved 259 cases of HER2+/APO. Most HER2+/APO were SR negative (65%). HER2+/APO were more prevalent in the 80+ age group (24.7% vs. 15.7%, p p p = 0.019). This was particularly evident between SR− subgroups (10.4% in HER2+/SR−/NST vs. 4.2% in HER2+/SR−/APO, p = 0.008) and was reaffirmed in breast cancer-specific survival in univariate analysis (p = 0.03). Other than race and SR status, HER2+/APO subgroups did not differ in clinicopathological parameters. Conclusions Our study confirms the rarity of the APO and reveals that SR status in APO does not affect these patients' prognosis. HER2+/APO tumors tend to have a less aggressive phenotype and a more favorable outcome despite a markedly lower ER/PR positivity.
Databáze: OpenAIRE
Externí odkaz: